Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 2/20 | 0.33 |
| ▸ | LDHB | P07195 | 2/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409022 | 0.90 | MLYCD (0.35) | MLYCD | |
| SCHEMBL3405824 | 0.89 | MLYCD (0.34) | MLYCD | |
| SCHEMBL3410531 | 0.88 | HSD17B10 (0.37) | MLYCDLDHALDHB | |
| SCHEMBL3406656 | 0.88 | MLYCD (0.43) | MLYCDFPR2CLK2FFAR2 | |
| SCHEMBL3409502 | 0.87 | MLYCD (0.35) | MLYCD | |
| SCHEMBL3402046 | 0.87 | MLYCD (0.33) | MLYCD | |
| SCHEMBL3403716 | 0.86 | MLYCD (0.32) | MLYCD | |
| SCHEMBL2861041 | 0.86 | MLYCD (0.45) | MLYCDFPR2 | |
| SCHEMBL3401944 | 0.86 | MLYCD (0.41) | MLYCDCLK2FFAR2 | |
| SCHEMBL3408237 | 0.83 | FBP1 (0.32) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370260-B1 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-11-24 | — | — | EP | claimed |
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | ME1, ME3, ME2 | MLYCD 4/4885FPR2 4093/4885MCHR1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.